title: Role of Rip2 in development of tumor-infiltrating MDSCs and bladder cancer metastasis.
abstract: Tumor invasion and metastases represent a complex series of molecular events that portends a poor prognosis. The contribution of inflammatory pathways mediating this process is not well understood. Nod-like receptors (NLRs) of innate immunity function as intracellular sensors of pathogen motifs and danger molecules. We propose a role of NLRs in tumor surveillance and in programming tumor-infiltrating lymphocytes (TILs). In this study, we examined the downstream serine/threonine and tyrosine kinase Rip2 in a murine model of bladder cancer. In Rip2-deficient C57Bl6 mice, larger orthotopic MB49 tumors developed with more numerous and higher incidence of metastases compared to wild-type controls. As such, increased tumor infiltration of CD11b+ Gr1hi myeloid-derived suppressor cells (MDSCs) with concomitant decrease in T cells and NK cells were observed in Rip2-deficient tumor bearing animals using orthotopic and subcutaneous tumor models. Rip2-deficient tumors showed enhanced epithelial-to-mesenchymal transition, with elevated expression of zeb1, zeb2, twist, and snail in the tumor microenvironment. We found that the absence of Rip2 plays an intrinsic role in fostering the development of granulocytic MDSCs by an autocrine and paracrine effect of granulocytic colony stimulating factor (G-CSF) expression. Our findings suggest that NLR pathways may be a novel modality to program TILs and influence tumor metastases.
authors.affiliation: Department of Urology, Broad Stem Cell Research Center, Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California, United States of America.
authors.forename: Hanwei
authors.initials: H
authors.lastname: Zhang
authors.affiliation: Department of Urology, Broad Stem Cell Research Center, Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California, United States of America.
authors.forename: Arnold I
authors.initials: AI
authors.lastname: Chin
mesh_terms: D000818:Animals; D045744:Cell Line, Tumor; D058750:Epithelial-Mesenchymal Transition; D005260:Female; D016246:Lymphocytes, Tumor-Infiltrating / Q000473:pathology*; D008810:Mice, Inbred C57BL; D022423:Myeloid Cells / Q000378:metabolism* / Q000473:pathology; D009362:Neoplasm Metastasis; D053475:Receptor-Interacting Protein Serine-Threonine Kinase 2; D053422:Receptor-Interacting Protein Serine-Threonine Kinases / Q000172:deficiency / Q000378:metabolism*; D047368:Tumor Burden; D001749:Urinary Bladder Neoplasms / Q000378:metabolism* / Q000473:pathology*
chemical_list: D053475:Receptor-Interacting Protein Serine-Threonine Kinase 2; D053422:Receptor-Interacting Protein Serine-Threonine Kinases; C506255:Ripk2 protein, mouse
references.citation: Cancer Microenviron. 2012 Aug;5(2):151-64
references.pmid: 22190050
references.citation: J Leukoc Biol. 2011 Feb;89(2):311-7
references.pmid: 21106641
references.citation: J Cancer. 2013;4(1):3-11
references.pmid: 23386900
references.citation: J Immunol. 2008 Oct 15;181(8):5791-802
references.pmid: 18832739
references.citation: J Interferon Cytokine Res. 2006 Aug;26(8):511-20
references.pmid: 16881862
references.citation: Cold Spring Harb Perspect Biol. 2009 Dec;1(6):a003129
references.pmid: 20457567
references.citation: Nature. 2002 Mar 14;416(6877):190-4
references.pmid: 11894097
references.citation: Immunity. 2011 Jan 28;34(1):75-84
references.pmid: 21236705
references.citation: PLoS Biol. 2011 Sep;9(9):e1001162
references.pmid: 21980263
references.citation: Nat Med. 2005 Dec;11(12):1314-21
references.pmid: 16288283
references.citation: Oncogene. 2007 Feb 1;26(5):711-24
references.pmid: 16862183
references.citation: Int J Cancer. 2012 Mar 1;130(5):1109-19
references.pmid: 21480223
references.citation: Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14739-44
references.pmid: 20679225
references.citation: Cancer Res. 2010 Apr 1;70(7):2595-603
references.pmid: 20233880
references.citation: PLoS One. 2011;6(9):e22356
references.pmid: 21931591
references.citation: Nature. 2002 Mar 14;416(6877):194-9
references.pmid: 11894098
references.citation: Science. 2006 Sep 29;313(5795):1960-4
references.pmid: 17008531
references.citation: Urol Oncol. 2008 Jul-Aug;26(4):341-5
references.pmid: 18593617
references.citation: Curr Biol. 2004 Dec 29;14(24):2217-27
references.pmid: 15620648
references.citation: Immunology. 2009 Oct;128(2):185-95
references.pmid: 19740375
references.citation: Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):3967-72
references.pmid: 17360461
references.citation: J Mol Cell Biol. 2013 Jun;5(3):207-9
references.pmid: 23532593
references.citation: Science. 2010 Jan 15;327(5963):291-5
references.pmid: 20075244
references.citation: Immunity. 2011 Apr 22;34(4):566-78
references.pmid: 21511185
references.citation: J Biol Chem. 2009 Jul 17;284(29):19183-8
references.pmid: 19473975
references.citation: PLoS One. 2011;6(11):e27690
references.pmid: 22110722
references.citation: J Clin Invest. 2013 Feb;123(2):700-11
references.pmid: 23281400
references.citation: J Leukoc Biol. 2003 Aug;74(2):277-86
references.pmid: 12885945
references.citation: J Biol Chem. 1998 May 15;273(20):12296-300
references.pmid: 9575181
references.citation: Clin Cancer Res. 2012 Jan 15;18(2):336-41
references.pmid: 22142824
references.citation: Cancer Discov. 2011 Jun;1(1):54-67
references.pmid: 22039576
references.citation: Anticancer Res. 2012 Sep;32(9):3775-83
references.pmid: 22993319
references.citation: PLoS One. 2012;7(2):e31524
references.pmid: 22348096
references.citation: Cancer Res. 1977 Aug;37(8 Pt 2):2918-29
references.pmid: 406041
references.citation: Eur J Immunol. 2011 May;41(5):1445-55
references.pmid: 21469090
references.citation: Nat Rev Cancer. 2012 Mar 15;12(4):298-306
references.pmid: 22419253
references.citation: PLoS One. 2013;8(2):e54841
references.pmid: 23418431
references.citation: Mutagenesis. 2012 May;27(3):319-22
references.pmid: 22075569
references.citation: PLoS One. 2012;7(6):e38773
references.pmid: 22701711
references.citation: PLoS Med. 2005 Sep;2(9):e284
references.pmid: 16124834
references.citation: Cancer Res. 2012 Aug 15;72(16):3977-86
references.pmid: 22719066
references.citation: Curr Opin Immunol. 2010 Aug;22(4):428-34
references.pmid: 20605429
references.citation: Immunity. 2011 May 27;34(5):665-79
references.pmid: 21616436
references.citation: J Immunol. 2007 Jul 15;179(2):977-83
references.pmid: 17617589
references.citation: Breast Cancer Res. 2004;6(3):R157-69
references.pmid: 15084239
references.citation: Cytokine. 2012 Aug;59(2):423-32
references.pmid: 22617682
references.citation: Cancer Res. 1990 Jul 1;50(13):3843-7
references.pmid: 2191767
references.citation: Cancer Res. 1984 Jul;44(7):3051-4
references.pmid: 6373001
references.citation: Genes Dev. 2010 Dec 1;24(23):2666-77
references.pmid: 21123652
references.citation: J Immunol. 2007 Feb 15;178(4):2380-6
references.pmid: 17277144